Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | PCNA | P12004 | 1/20 | 0.38 |
| ▸ | IL1RN | P18510 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL1921535 | 0.99 | SLC7A5 (0.49) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL1921644 | 0.97 | SLC7A5 (0.51) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL1921852 | 0.94 | SLC7A5 (0.55) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL3121863 | 0.93 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL1921493 | 0.92 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL1649464 | 0.92 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL26598018 | 0.92 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL19712182 | 0.91 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL19712178 | 0.91 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BLNPEP | |
| Tyrosine SCHEMBL28098884 | 0.91 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BLNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4800481-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-20100298227-A1 | Treatment of autoimmune conditions with Copolymer 1 and related copolymers | President and Fellows of Harvard College and Yeda Research | 2010-11-25 | — | — | US | claimed |
| US-20080207526-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-08-28 | — | — | US | claimed |
| US-20040006022-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-08 | — | — | US | claimed |
| EP-1098902-A4 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RES & DEV (IL) | 2002-07-24 | — | — | EP | claimed |
| EP-1105414-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | President And Fellows of Harvard College (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1098902-A1 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-05-16 | — | — | EP | claimed |
| WO-2000005250-A9 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RES & DEV (IL) | 2000-10-12 | — | — | WO | claimed |
| WO-2000005250-A1 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO., LTD (IL) | 2000-02-03 | — | — | WO | claimed |
| WO-2000005249-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-03 | — | — | WO | claimed |
| EP-2013628-B1 | METHODS OF EVALUATING PEPTIDE MIXTURES | MOMENTA PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9066905-B2 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2848627-A2 | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2015-03-18 | — | — | EP | disclosed |
| US-8927292-B2 | Methods of evaluating peptide mixtures | MOMENTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8921116-B2 | Methods of evaluating diethylamide in peptide mixtures for the preparation of glatiramer acetate | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20060194725-A1 | Reducing the severity of symptoms of multiple sclerosis comprising the step of administering a random copolymer where a dosage is delivered to the subject one week after the preceding dosage; YFAK (L-tyrosine, L-phenylalanine, L-alanine and L-lysine) molar ratio of 1.0:1.2:XA:6.0 (XA=18.0-30.0) | PEPTIMMUNE ACQUISITION, LLC | 2006-08-31 | — | — | US | disclosed |
| US-20060189527-A1 | Reducing the severity of symptoms of multiple sclerosis comprising the step of administering a random copolymer where a dosage is delivered to the subject one week after the preceding dosage; YFAK (L-tyrosine, L-phenylalanine, L-alanine and L-lysine) molar ratio of 1.0:1.2:XA:6.0 (XA=18.0-30.0) | PEPTIMMUNE ACQUISITION, LLC | 2006-08-24 | — | — | US | disclosed |
| WO-2005120542-A2 | METHODS OF TREATING DISEASE WITH RANDOM COPOLYMERS | PEPTIMMUNE, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005112972-A1 | METHODS OF TREATING DISEASE WITH RANDOM COPOLYMERS | PEPTIMMUNE, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20040006022-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-08 | — | — | US | disclosed |